Literature DB >> 31012004

A Novel Dipeptide Ligand of TSPO.

O A Deeva1, A S Pantileev1, I V Rybina1, M A Yarkova1, T A Gudasheva2, S B Seredenin1.   

Abstract

On the basis of the first dipeptide ligand of TSPO, N-carbobenzoxy-L-tryptophanyl-L-isoleucine amide (GD-23), which was obtained by us earlier, we synthesized a new dipeptide, N-phenylpropionyl-L-tryptophanyl-L-leucine amide (GD-102). GD-102 exhibited anxiolytic activity in the open field test in BALB/c mice and in the elevated plus maze test in ICR mice. The minimum effective dose of GD-102 was one order of magnitude lower than that of GD-23. Compound PK11195, a selective antagonist of TSPO, completely blocked the anxiolytic activity of GD-102, which testified to the involvement of TSPO in the realization of the anxiolytic effect of GD-102. The results were confirmed by molecular docking data.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31012004     DOI: 10.1134/S1607672919010046

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN: 1607-6729            Impact factor:   0.788


  2 in total

Review 1.  Insight into the Structural Features of TSPO: Implications for Drug Development.

Authors:  Jean-Jacques Lacapere; Luminita Duma; Stephanie Finet; Michael Kassiou; Vassilios Papadopoulos
Journal:  Trends Pharmacol Sci       Date:  2019-12-18       Impact factor: 14.819

2.  The New Dipeptide TSPO Ligands: Design, Synthesis and Structure-Anxiolytic Activity Relationship.

Authors:  Tatiana A Gudasheva; Olga A Deeva; Andrey S Pantileev; Grigory V Mokrov; Inna V Rybina; Milada A Yarkova; Sergei B Seredenin
Journal:  Molecules       Date:  2020-11-04       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.